What is Coherus Oncology Operating Cash Flow per Share?
Coherus Oncology's operating cash flow per share for the
three
months ended in Mar. 2025 was $-0.22.
Coherus Oncology's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.01.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 28.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Coherus Oncology's Operating Cash Flow per Share or its related term are showing as below:
CHRS'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -42.3 Med: 5.6 Max: 41.3
Current: 28.9
During the past 13 years, Coherus Oncology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 41.30% per year. The lowest was -42.30% per year. And the median was 5.60% per year.
CHRS's 3-Year OCF Growth Rate is ranked better than 71.29% of 1219
companies
in the Biotechnology industry
Industry Median: 9.2
vs CHRS: 28.90
Coherus Oncology Operating Cash Flow per Share Historical Data
The historical data trend for Coherus Oncology's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Coherus Oncology Operating Cash Flow per Share Chart
Competitive Comparison of Coherus Oncology's Operating Cash Flow per Share
For the Biotechnology subindustry, Coherus Oncology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Coherus Oncology's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHRS has been successfully added to your 